Abbisko Drug Receives Orphan Drug Designation in U.S.

AI Briefing

• – Abbisko Pharmaceuticals' experimental treatment for rare genetic disorder receives FDA approval as first orphan drug designation in the U.S.
• – The designation provides Abbisko with a seven-year market exclusivity period to develop and market the drug
• – The treatment aims to provide a new treatment option for patients with a rare genetic disorder